AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36058795 — intervention group
Group type: EXPERIMENTAL
Intervention: CCHFV vaccine trial
Number of subjects: 150
Study 36058795 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased expected vaccine efficacy > 60%
Number of subjects: 150
Study 34626502 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab (2.5 mg)
Number of subjects: 1545
Study 34626502 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab (5 mg)
Number of subjects: 1545
Study 34626502 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 1545
Study 34626502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1545
Study 36106146 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (0.3 g kg FFM−1)
Number of subjects: 10
Study 36106146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 34537725 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Epidural Anaesthesia (SEA)
Number of subjects: 60
Study 34537725 — intervention group
Group type: EXPERIMENTAL
Intervention: High Epidural Anaesthesia (HEA)
Number of subjects: 60
Study 34537725 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Paravertebral Anaesthesia (PVA)
Number of subjects: 60
Study 34537725 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuss procedure overall
Number of subjects: 60
Study 32299513 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX01 plus cyclophosphamide, doxorubicin, vincristine, and prednisone (H-CHOP)
Number of subjects: 407
Study 32299513 — intervention group
Group type: COMPARATOR
Intervention: Reference rituximab plus CHOP (R-CHOP)
Number of subjects: 407
Study 34132024 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical C. rotundus oil
Number of subjects: 153
Study 34132024 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 153
Study 34132024 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 153
Study 34319398 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin, 10 mg, once daily
Number of subjects: 4744
Study 34319398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study 35739531 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario-based repetition strategy
Number of subjects: 162
Study 35739531 — intervention group
Group type: COMPARATOR
Intervention: Repetition (classical presentation)
Number of subjects: 162
Study 32666599 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplanted human fetal ganglionic eminence (treatment group)
Number of subjects: 54
Study 32666599 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (control group)
Number of subjects: 54
Study 32666599 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 54
Study 36202546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial volume (ICV) measured by SAS
Number of subjects: 133
Study 36202546 — intervention group
Group type: COMPARATOR
Intervention: Intracranial volume (ICV) measured by XYZ
Number of subjects: 133
Study 36202546 — intervention group
Group type: EXPERIMENTAL
Intervention: ICH volume (ICHV) measured by ABC/2
Number of subjects: 133
Study 36202546 — intervention group
Group type: EXPERIMENTAL
Intervention: ICHV/ICV and ICHV/CPV
Number of subjects: 133
Study 36202546 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline shift and cistern effacement at baseline
Number of subjects: 133
Study 36202546 — intervention group
Group type: EXPERIMENTAL
Intervention: Old infarcts, leukoaraiosis, and brain atrophy
Number of subjects: 133
Study 36240903 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD
Number of subjects: 655
Study 36240903 — intervention group
Group type: COMPARATOR
Intervention: Copper IUD
Number of subjects: 655
Study 33210950 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision trees
Number of subjects: 500
Study 33210950 — intervention group
Group type: EXPERIMENTAL
Intervention: Online planning tool
Number of subjects: 500
Study 33210950 — intervention group
Group type: EXPERIMENTAL
Intervention: Infographics
Number of subjects: 500
Study 34741886 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 23
Study 34741886 — intervention group
Group type: EXPERIMENTAL
Intervention: HER4 mutations
Number of subjects: 23
Study 34741886 — intervention group
Group type: EXPERIMENTAL
Intervention: E395K, G815R, or R929W HER2 mutations
Number of subjects: 23
Study 34741886 — intervention group
Group type: EXPERIMENTAL
Intervention: Other second/third-generation (2G/3G) TKIs
Number of subjects: 23
Study 32472172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab alone (n=23)
Number of subjects: 47
Study 32472172 — intervention group
Group type: COMPARATOR
Intervention: Combination of intravitreal ranibizumab and panretinal photocoagulation (PRP) (n=24)
Number of subjects: 47
Study 32472172 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ranibizumab alone and combination)
Number of subjects: 47
Study 33992882 — intervention group
Group type: EXPERIMENTAL
Intervention: Low monoenergetic images
Number of subjects: 42
Study 33992882 — intervention group
Group type: COMPARATOR
Intervention: Conventional images
Number of subjects: 42
Study 35641440 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Immersion Simulation system (FIS)
Number of subjects: 80
Study 35641440 — intervention group
Group type: COMPARATOR
Intervention: Air-fluidised bed (AFB)
Number of subjects: 80
Study 35641440 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Immersion Simulation system (FIS) with ClimateCare®
Number of subjects: 80
Study 33715064 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Anesthesia (CA)
Number of subjects: 35
Study 33715064 — intervention group
Group type: COMPARATOR
Intervention: Vibrational Anesthesia (VBA)
Number of subjects: 35
Study 33715064 — intervention group
Group type: COMPARATOR
Intervention: Computer-Controlled Local Anesthesia Device (CCLAD)
Number of subjects: 35
Study 33715064 — intervention group
Group type: COMPARATOR
Intervention: Disruptive Behavior (FLACC)
Number of subjects: 35
Study 33715064 — intervention group
Group type: COMPARATOR
Intervention: Anxiety (VPTm)
Number of subjects: 35
Study 33715064 — intervention group
Group type: COMPARATOR
Intervention: Physiological Parameters (SBP, DBP, HR, SpO2, RR)
Number of subjects: 35
Study 32236507 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (400 mg/d) for 2 years
Number of subjects: 908
Study 32236507 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 908
Study 35810751 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib plus nivolumab
Number of subjects: 91
Study 35810751 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib plus ipilimumab
Number of subjects: 91
Study 33551297 — intervention group
Group type: EXPERIMENTAL
Intervention: Male transobturator sling
Number of subjects: 380
Study 33551297 — intervention group
Group type: COMPARATOR
Intervention: Artificial urinary sphincter (AUS)
Number of subjects: 380
Study 33551297 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 380
Study 34641791 — intervention group
Group type: EXPERIMENTAL
Intervention: Doll Therapy (DT)
Number of subjects: 52
Study 34641791 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 52
Study 32812051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/daclatasvir
Number of subjects: 62
Study 32812051 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin
Number of subjects: 62
Study 35460287 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg (TIL100)
Number of subjects: 26
Study 35460287 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg (TIL200)
Number of subjects: 26
Study 35460287 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab (both dosages)
Number of subjects: 26
Study 34769704 — intervention group
Group type: EXPERIMENTAL
Intervention: VR with light pressure (VRL)
Number of subjects: 15
Study 34769704 — intervention group
Group type: EXPERIMENTAL
Intervention: VR with moderate pressure (VRM)
Number of subjects: 15
Study 34769704 — intervention group
Group type: COMPARATOR
Intervention: General warm up (GW)
Number of subjects: 15
Study 36172885 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 g mycoprotein (MYC; 31.4 g protein, 2.5 g leucine; n=12)
Number of subjects: 24
Study 36172885 — intervention group
Group type: COMPARATOR
Intervention: 38.2 g of a protein concentrate obtained from mycoprotein (PCM; 28.0 g protein, 2.5 g leucine; n=12)
Number of subjects: 24
Study 36172885 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MYC and PCM
Number of subjects: 24
Study 33768643 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal supplementation
Number of subjects: 635
Study 35180745 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral cutaneous branch (LCB) of the fourth intercostal nerve
Number of subjects: 19
Study 35180745 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cutaneous branch (ACB) of the third intercostal nerve
Number of subjects: 19
Study 34008421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 45
Study 34008421 — intervention group
Group type: COMPARATOR
Intervention: Aspirin or Clopidogrel (Control)
Number of subjects: 45
Study 36274187 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 1414
Study 36274187 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved biomass arm
Number of subjects: 1414
Study 36274187 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquified petroleum gas (LPG) arm
Number of subjects: 1414
Study 33151500 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide oral liquid formulation
Number of subjects: 400
Study 33151500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 32387408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 80 μg delivered via Breezhaler®
Number of subjects: 739
Study 32387408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 320 μg delivered via Breezhaler®
Number of subjects: 739
Study 32387408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 80 μg and 320 μg delivered via Breezhaler®
Number of subjects: 739
Study 32387408 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate 200 μg and 800 μg delivered via Twisthaler®
Number of subjects: 739
Study 35192784 — intervention group
Group type: EXPERIMENTAL
Intervention: Tested PCV13
Number of subjects: 1200
Study 35192784 — intervention group
Group type: COMPARATOR
Intervention: Control PCV13
Number of subjects: 1200
Study 33596092 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization in 60° of external rotation plus 30° of abduction (group 1)
Number of subjects: 112
Study 33596092 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic Bankart repair (group 2)
Number of subjects: 112
Study 33596092 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 112
Study 32124817 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 80
Study 32124817 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA) with 45° head rotation
Number of subjects: 80
Study 32124817 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA) with no head rotation
Number of subjects: 80
Study 32124817 — intervention group
Group type: COMPARATOR
Intervention: Volunteers
Number of subjects: 80
Study 33687555 — intervention group
Group type: EXPERIMENTAL
Intervention: MINST + NaOCl gel
Number of subjects: 40
Study 33687555 — intervention group
Group type: COMPARATOR
Intervention: MINST alone
Number of subjects: 40
Study 32394686 — intervention group
Group type: EXPERIMENTAL
Intervention: del Nido solution (DNS)
Number of subjects: 60
Study 32394686 — intervention group
Group type: COMPARATOR
Intervention: cold blood cardioplegia solution (CBCS)
Number of subjects: 60
Study 35984512 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ppm F/TMP/XE
Number of subjects: 120
Study 35984512 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% xylitol + 4% erythritol (XE)
Number of subjects: 120
Study 35984512 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ppm F + 0.2% TMP (200 ppm F/TMP)
Number of subjects: 120
Study 35984512 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100 ppm F
Number of subjects: 120
Study 35984512 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no F, TMP, XE)
Number of subjects: 120
Study 33617294 — intervention group
Group type: EXPERIMENTAL
Intervention: DECTA with 50% reduced iodine dose (300 mgI/kg)
Number of subjects: 65
Study 33617294 — intervention group
Group type: EXPERIMENTAL
Intervention: DECTA-80%
Number of subjects: 65
Study 33617294 — intervention group
Group type: EXPERIMENTAL
Intervention: DECTA-40%
Number of subjects: 65
Study 33617294 — intervention group
Group type: COMPARATOR
Intervention: SECTA with standard iodine dose (600 mgI/kg)
Number of subjects: 65
Study 33617294 — intervention group
Group type: EXPERIMENTAL
Intervention: DECTA
Number of subjects: 65
Study 33617294 — intervention group
Group type: COMPARATOR
Intervention: SECTA
Number of subjects: 65
Study 33965769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate exposure >25 mg/L (preconception)
Number of subjects: 1219140
Study 33965769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate exposure >25 mg/L (prenatal)
Number of subjects: 1219140
Study 33965769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate exposure >25 mg/L (postnatal)
Number of subjects: 1219140
Study 33965769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate exposure (continuous)
Number of subjects: 1219140
Study 35881863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cacao butter
Number of subjects: 72
Study 35881863 — intervention group
Group type: COMPARATOR
Intervention: Mother's milk
Number of subjects: 72
Study 32642971 — intervention group
Group type: EXPERIMENTAL
Intervention: PGX (15–20 g/day)
Number of subjects: 290
Study 32642971 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isocaloric rice flour, 6.4–8.6 g/day)
Number of subjects: 290
Study 32830200 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine treatment (n = 71)
Number of subjects: 130
Study 32830200 — intervention group
Group type: COMPARATOR
Intervention: Non-gemcitabine treatment (n = 59)
Number of subjects: 130
Study 32830200 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort gemcitabine subgroup (n = 94)
Number of subjects: 130
Study 32830200 — intervention group
Group type: COMPARATOR
Intervention: Validation cohort non-gemcitabine subgroup (n = 19)
Number of subjects: 130
Study 33948084 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoporous delivery system
Number of subjects: 3
Study 33948084 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) group
Number of subjects: 3
Study 33948084 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 33233275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultivar BRS Moema
Number of subjects: 2
Study 33233275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultivar Airetama
Number of subjects: 2
Study 33233275 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall chemical composition
Number of subjects: 2
Study 33233275 — intervention group
Group type: EXPERIMENTAL
Intervention: pH
Number of subjects: 2
Study 33233275 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR and PHE
Number of subjects: 2
Study 33233275 — intervention group
Group type: EXPERIMENTAL
Intervention: MASS and PLAS
Number of subjects: 2
Study 37779541 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3772847 (10 mg/kg intravenous)
Number of subjects: 69
Study 37779541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 34060142 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (diaper with emollient and apertures on the inner liner, acidic pH-buffered wipe)
Number of subjects: 0
Study 34060142 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (non-emollient, non-aperture containing topsheet and wipe with limited buffering capacity)
Number of subjects: 0
Study 32044419 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin (PacCis)‐CRT; paclitaxel 20 mg/m2 on days 2, 5, 8, 11 and 25, 30, 33, 36; cisplatin 20 mg/m2, days 1‐4 and 29‐32; RT to a total dose of 63.6 Gy
Number of subjects: 221
Study 32044419 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil/cisplatin (CisFU)‐CRT; fluorouracil 600 mg/m2; cisplatin 20 mg/m2, days 1‐5 and 29‐33; RT: 70.6 Gy
Number of subjects: 221
Study 32044419 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin (PacCis)‐CRT
Number of subjects: 221
Study 32044419 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil/cisplatin (CisFU)‐CRT
Number of subjects: 221
Study 35388330 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis
Number of subjects: 92
Study 35388330 — intervention group
Group type: COMPARATOR
Intervention: Hemodiafiltration
Number of subjects: 92
Study 33886898 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational technology intervention
Number of subjects: 73
Study 33886898 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no educational technology)
Number of subjects: 73
Study 32671658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue virus infection (DV cohort)
Number of subjects: 29365
Study 32671658 — intervention group
Group type: COMPARATOR
Intervention: Non-dengue virus control (non-DV cohort)
Number of subjects: 29365
Study 35251584 — intervention group
Group type: EXPERIMENTAL
Intervention: Subanaesthetic dose of ketamine
Number of subjects: 90
Study 35251584 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and dexmedetomidine
Number of subjects: 90
Study 35251584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb nerve block combined with local infiltration analgesia
Number of subjects: 90
Study 33674366 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS-TLIF
Number of subjects: 0
Study 33674366 — intervention group
Group type: COMPARATOR
Intervention: O-TLIF
Number of subjects: 0
Study 32815661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (pharmacological SBP reduction to <120 mm Hg upon enrollment)
Number of subjects: 289
Study 32815661 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (clinical follow-up till SBP goes above 140 mm Hg and then starting medications to keep SBP <140 mm Hg)
Number of subjects: 289
Study 32815661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 289
Study 34416229 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose GSNO (up to 20 nmol/kg/min)
Number of subjects: 21
Study 34416229 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GSNO (up to 60 nmol/kg/min)
Number of subjects: 21
Study 34416229 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 21
Study 34083339 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised 6-month physical activity programme consisting of supervised exercise sessions and unsupervised sessions with phone follow-ups.
Number of subjects: 40
Study 35287112 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day anthocyanin-rich blackcurrant extract for 7 days
Number of subjects: 12
Study 35287112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 32324307 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-enabled home-based exercise therapy (HBET) with daily exercise reminders and educational content, weekly phone-based coaching sessions.
Number of subjects: 15
Study 32324307 — intervention group
Group type: COMPARATOR
Intervention: Walking advice (control group).
Number of subjects: 15
Study 34655908 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma cues
Number of subjects: 51
Study 34655908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis cues
Number of subjects: 51
Study 34655908 — intervention group
Group type: COMPARATOR
Intervention: Neutral cues
Number of subjects: 51
Study 33848805 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate SBRT (36–48 Gy in 6–8 fractions)
Number of subjects: 125
Study 33848805 — intervention group
Group type: COMPARATOR
Intervention: Control (ADT plus chemotherapy)
Number of subjects: 125
Study 37802824 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical syndrome-based medicine incorporating optimal clinical experience
Number of subjects: 0
Study 37802824 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese medicine (TCM) practices
Number of subjects: 0
Study 32515696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial mechanical thrombectomy plus internal carotid artery stenting (and at least one antiplatelet therapy)
Number of subjects: 432
Study 32515696 — intervention group
Group type: COMPARATOR
Intervention: Intracranial mechanical thrombectomy alone
Number of subjects: 432
Study 32058883 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training (2 hours)
Number of subjects: 93
Study 32058883 — intervention group
Group type: COMPARATOR
Intervention: Problem-based scenarios alone
Number of subjects: 93
Study 32058883 — intervention group
Group type: COMPARATOR
Intervention: Comparison of experimental and control groups post-test
Number of subjects: 93
Study 35780799 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐typeable Haemophilus influenzae–Moraxella catarrhalis vaccine
Number of subjects: 0
Study 35780799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34123370 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg) evening administration
Number of subjects: 0
Study 34123370 — intervention group
Group type: COMPARATOR
Intervention: Empagliflozin (10 mg) morning administration
Number of subjects: 0
Study 34479746 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-centered message
Number of subjects: 702
Study 34479746 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-centered message
Number of subjects: 702
Study 34479746 — intervention group
Group type: EXPERIMENTAL
Intervention: Country-centered message
Number of subjects: 702
Study 34479746 — intervention group
Group type: COMPARATOR
Intervention: No message
Number of subjects: 702
Study 34510212 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous medical food ketone formulation (KF)
Number of subjects: 13